3 August 2022 - A U.S. appeals court on Monday affirmed that AbbVie Inc did not unlawfully block competition by building up a "thicket" of patents related to its blockbuster arthritis drug Humira.

AbbVie's 132 patents related to Humira do not violate antitrust law, U.S. Circuit Judge Frank Easterbrook said Monday, rejecting claims that the patents wrongly kept generic competitors out of the market years after the original patent on Humira expired.

Read Reuters article